CAS 877963-94-5

2-[(4-cyclopropanecarbonylpiperazin-1-yl)methyl]-2,3-dihydro-1,2-benzothiazol-3-one

CAS : 877963-94-5

Formule : C₁₆H₁₉N₃O₂S

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 317.4060

Ref: IN-DA01BCFP

LOC14

CAS : 877963-94-5

LOC14

Degré de pureté : ≥98%

Masse moléculaire : 317.41g/mol

Ref: 54-BUP06128

LOC14

CAS : 877963-94-5

LOC14 to be the most potent PDI inhibitor reported to date( EC50 : 500 nM)

Formule : C₁₆H₁₉N₃O₂S

Degré de pureté : 99.62%

Couleur et forme : Solid

Masse moléculaire : 317.41

Ref: TM-T5534

2-[(4-cyclopropanecarbonylpiperazin-1-yl)methyl]-2,3-dihydro-1,2-benzothiazol-3-one

CAS : 877963-94-5

Degré de pureté : 98%

Masse moléculaire : 317.410003662109

Ref: 10-F864095

LOC14

CAS : 877963-94-5

LOC14 is a peptide derived from the human immunodeficiency virus (HIV) that has been shown to have anticancer activity. It was found to be active against tumor cells, but not normal cells, in culture. LOC14 is neuroprotective and prevents the activation of microglia in response to an inflammatory insult. This peptide also modulates the production of pro-inflammatory cytokines by inhibiting the phosphorylation of NF-κB and by preventing the degradation of IκBα protein. LOC14 inhibits food poisoning caused by enterotoxigenic Escherichia coli (ETEC) and other bacterial pathogens. It also has anti-inflammatory effects against inflammatory diseases such as rheumatoid arthritis and colitis.
LOC14 inhibits HIV infectivity by binding to gp41, which is a major component of HIV's envelope on the surface of infected cells. This interaction prevents gp41 from interacting with CD4 receptors on uninfected cells, thus

Formule : C₁₆H₁₉N₃O₂S

Degré de pureté : Min. 95%

Masse moléculaire : 317.41 g/mol

Ref: 3D-CKB96394